Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

Compare

65 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CAI Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Caris

Life Sciences, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CAI Stock 12 Month Forecast

Average Price Target

$32.88

▲(17.26% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc. in the last 3 months. The average price target is $32.88 with a high forecast of $38.00 and a low forecast of $31.00. The average price target represents a 17.26% change from the last price of $28.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","32":"$32","39":"$39","28.5":"$28.5","35.5":"$35.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,28.5,32,35.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,27.393846153846155,28.27769230769231,29.161538461538463,30.045384615384616,30.92923076923077,31.813076923076924,32.69692307692308,33.580769230769235,34.464615384615385,35.348461538461535,36.23230769230769,37.11615384615385,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,27,27.490000000000002,27.98,28.470000000000002,28.96,29.450000000000003,29.94,30.430000000000003,30.92,31.410000000000004,31.900000000000002,32.39,{"y":32.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.51,26.855384615384615,27.200769230769232,27.546153846153846,27.891538461538463,28.236923076923077,28.582307692307694,28.927692307692308,29.273076923076925,29.61846153846154,29.963846153846156,30.30923076923077,30.654615384615383,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$38.00

Average Price Target$32.88

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Doug SchenkelWolfe Research

Wolfe Research

$32

Buy

14.12%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research

Daniel BrennanTD Cowen

TD Cowen

$32

Buy

14.12%

Upside

Initiated

07/14/25

Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences

Michael RyskinBank of America Securities

Bank of America Securities

$31

Buy

10.56%

Upside

Initiated

07/14/25

Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating

Patrick B DonnellyCiti

Citi

$34

Buy

21.26%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with a Buy at CitiCaris Life Sciences initiated with a Buy at Citi

Vijay KumarEvercore ISI

Evercore ISI

$33

Buy

17.69%

Upside

Initiated

07/14/25

Evercore ISI Initiates a Buy Rating on Caris Life Sciences, Inc. (CAI)

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$31

Buy

10.56%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Overweight at JPMorganCaris Life Sciences initiated with an Overweight at JPMorgan

Subbu NambiGuggenheim

Guggenheim

$32

Buy

14.12%

Upside

Initiated

07/13/25

Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim

Mark MassaroBTIG

BTIG

$38

Buy

35.52%

Upside

Initiated

07/13/25

Caris Life Sciences initiated with a Buy at BTIGCaris Life Sciences initiated with a Buy at BTIG

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Doug SchenkelWolfe Research

Wolfe Research

$32

Buy

14.12%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research

Daniel BrennanTD Cowen

TD Cowen

$32

Buy

14.12%

Upside

Initiated

07/14/25

Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences

Michael RyskinBank of America Securities

Bank of America Securities

$31

Buy

10.56%

Upside

Initiated

07/14/25

Caris Life Sciences: Strong Market Position and Growth Potential Justify Buy Rating

Patrick B DonnellyCiti

Citi

$34

Buy

21.26%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with a Buy at CitiCaris Life Sciences initiated with a Buy at Citi

Vijay KumarEvercore ISI

Evercore ISI

$33

Buy

17.69%

Upside

Initiated

07/14/25

Evercore ISI Initiates a Buy Rating on Caris Life Sciences, Inc. (CAI)

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$31

Buy

10.56%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Overweight at JPMorganCaris Life Sciences initiated with an Overweight at JPMorgan

Subbu NambiGuggenheim

Guggenheim

$32

Buy

14.12%

Upside

Initiated

07/13/25

Caris Life Sciences initiated with a Buy at GuggenheimCaris Life Sciences initiated with a Buy at Guggenheim

Mark MassaroBTIG

BTIG

$38

Buy

35.52%

Upside

Initiated

07/13/25

Caris Life Sciences initiated with a Buy at BTIGCaris Life Sciences initiated with a Buy at BTIG

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caris Life Sciences, Inc.

1 Month

xxx

Success Rate

1/1 ratings generated profit

Average Return

+11.20%

initiated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +11.20% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+11.20%

initiated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +11.20% per trade.

1 Year

Subbu NambiGuggenheim

Success Rate

1/1 ratings generated profit

Average Return

+9.20%

initiated a buy rating 26 days ago

Copying Subbu Nambi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.20% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+11.20%

initiated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +11.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAI Analyst Recommendation Trends

Rating

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CAI has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CAI average Analyst price target in the past 3 months is 32.88.

Each month's total comprises the sum of three months' worth of ratings.

CAI Financial Forecast

No data currently available

CAI Earnings Forecast

Next quarter’s earnings estimate for CAI is -$0.22 with a range of -$0.38 to -$0.16. The previous quarter’s EPS was ―. CAI beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year CAI has Preformed in-line its overall industry.

No data currently available

CAI Sales Forecast

Next quarter’s sales forecast for CAI is $138.04M with a range of $132.90M to $141.00M. The previous quarter’s sales results were ―. CAI beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year CAI has Preformed in-line its overall industry.

CAI Stock Forecast FAQ

What is CAI’s average 12-month price target, according to analysts?

Based on analyst ratings, Caris Life Sciences, Inc.’s 12-month average price target is 32.88.

What is CAI’s upside potential, based on the analysts’ average price target?

Caris Life Sciences, Inc. has 17.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CAI a Buy, Sell or Hold?

Caris Life Sciences, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Caris Life Sciences, Inc.’s price target?

The average price target for Caris Life Sciences, Inc. is 32.88. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $31.00. The average price target represents 17.26% Increase from the current price of $28.04.

What do analysts say about Caris Life Sciences, Inc.?

Caris Life Sciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CAI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

CAI Analyst Ratings

CAI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Caris Life Sciences, Inc.

CAI Analyst Recommendation Trends

CAI Financial Forecast

CAI Earnings Forecast

CAI Sales Forecast

CAI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts